Amar U. Kishan, MD, establishes why individualized ADT decision-making remains an unsolved problem in intermediate-risk prostate cancer.
Rethinking ADT: AI Biomarkers in Intermediate-Risk Prostate Cancer
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves generic Ga-68 PSMA-11 radiodiagnostic for prostate cancer
2
Clinical Application of MMAI Score in Patients with Prostate Cancer
3
Kevin Zorn, MD, on selecting among different MIST options for BPH
4
Nicole L. Miller, MD, FACS, on assessing patients after BPH treatment failure
5